|
DDNEWS is pleased to share with its readers periodic surveys conducted with Mizuho Securities USA Inc. (MSUSA) about various life-science research trends and topics.
MSUSA
is the U.S. investment banking subsidiary of the Mizuho Financial Group in Tokyo, one of the world's largest banking organizations. MSUSA will use the data collected in these surveys to help gauge spending in the pharmaceutical and biotech sectors.
If you are interested in the results from any of these surveys, please e-mail Peter Lawson of MSUSA's Equity Research Department at peter.lawson@us.mizuho-sc.com.
NEXT: JULY 2013 - STEM CELL RESEARCH TAKE THE SURVEY NOW AT: https://www.surveymonkey.com/s/52PWYBH
DECEMBER 2013 - PERSONALIZED MEDICINE OUR EXCLUSIVE REPORTS: Survey highlights link between companion diagnostics and
future of cancer research
DDNEWS readers say molecular diagnostics are essential part of oncology drug development JANUARY 2013:Readers predict growth in genomic sequencing market
Survey indicates shift from clinical sequencing to
consumer-driven sequencing in seven years
DECEMBER 2012: DDNEWS Market Research: CDx expected to become standard of care
within next decade Readers say 30 percent of biopharma industry’s drug sales will require companion diagnostics in next five years. Stem cell research survey indicates optimism, growth
expected in 2013
JUNE 2012: Use of biomarkers in cancer research Respondents have a dim short-term view—but a brighter long-term view—for spending on and use of biomarkers. JANUARY 2012: Life sciences tools and technology market expected to remain flat Life-science researchers and industry participants expect funding for tools and technology to remain flat in the next five years, but the outlook for laboratory equipment and its manufacturers is still more positive than funding for the genomics market.
DECEMBER 2011: Survey on trends in CRO market shows outsourcing is on the rise
Outsourcing is on the rise as contract research organizations (CROs) gain popularity, with respondents in a new survey conducted by Mizuho Securities USA Inc. reporting that they expect a solid 41 percent of biopharma’s pipeline will be outsourced in five years, with expectations for this number to hit 55 percent in 10 years.
|
|
||
|
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|